IDENTIFICATION OF A SUBGROUP OF GRAVES-DISEASE PATIENTS AT HIGHER RISK FOR SEVERE OPHTHALMOPATHY AFTER RADIOIODINE

被引:34
作者
BARTH, A
PROBST, P
BURGI, H
机构
[1] BURGERSPITAL,DEPT MED,CH-4500 SOLOTHURN,SWITZERLAND
[2] BURGERSPITAL,INST MED RADIOL,CH-4500 SOLOTHURN,SWITZERLAND
关键词
GRAVES DISEASE; RADIOIODINE; ENDOCRINE OPHTHALMOPATHY; EXOPHTHALMOS;
D O I
10.1007/BF03346790
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
We have analyzed retrospectively the records of 89 patients with Graves' disease who were treated with radioiodine between 1980-88 and whose ophthalmopathy was recorded in a uniform manner initially and after 5 and 12 months. Moreover information on progression of eye disease was obtained by telephone for all patients after an average of 72 months. Pretreatment endocrine ophthalmopathy (class greater-than-or-equal-to 1 of classification of American Thyroid Association) was present in 34% of the patients. Eight patients developed proptosis over 20mm, 7 patients severe ophthalmopathy (classes 4 to 6), 5 patients required special treatment for eye disease. Among the 30 patients with initial ophthalmopathy, severe ophthalmopathy (5 of 30; p < 0.05) and proptosis > 20mm 16 of 30; p < 0.05) developed in significantly more cases than in patients with no pretreatment ophthalmopathy. The data suggest that hyperthyroid patients with pretreatment ophthalmopathy are at risk for developing severe ophthalmopathy after I-131 treatment.
引用
收藏
页码:209 / 212
页数:4
相关论文
共 50 条
  • [41] Serum CYR61 Levels are Associated with Graves' Ophthalmopathy and Smoking in Patients with Graves' Disease
    Cerri, Perparim
    Shahida, Bushra
    Lantz, Mikael
    Planck, Tereza
    HORMONE AND METABOLIC RESEARCH, 2022, 54 (03) : 168 - 174
  • [42] TRANSIENT HYPOTHYROIDISM AFTER I-131 THERAPY FOR GRAVES-DISEASE
    GOMEZ, N
    GOMEZ, JM
    ORTI, A
    GAVALDA, L
    VILLABONA, C
    LEYES, P
    SOLER, J
    ARNAIZ, NG
    JOURNAL OF NUCLEAR MEDICINE, 1995, 36 (09) : 1539 - 1542
  • [43] Serum Selenium Levels in Patients With Graves Disease With or Without Thyroid Ophthalmopathy
    Owji, Naser
    Moradi, Fatemeh
    Khalili, Mohammad Reza
    Jahanbani-Ardakani, Hamidreza
    ENDOCRINE PRACTICE, 2022, 28 (12) : 1216 - 1220
  • [44] DYNAMIC CHANGES OF TRAb AND TPOAb AFTER RADIOIODINE THERAPY IN GRAVES' DISEASE
    Dong, Q.
    Liu, X.
    Wang, F.
    Xu, Y.
    Liang, C.
    Du, W.
    Gao, G.
    ACTA ENDOCRINOLOGICA-BUCHAREST, 2017, 13 (01) : 72 - 76
  • [45] FACTORS AFFECTING THYROID-FUNCTION AFTER THYROIDECTOMY FOR GRAVES-DISEASE
    HUANG, CS
    WANG, M
    SHUN, CT
    LIAW, KY
    JOURNAL OF THE FORMOSAN MEDICAL ASSOCIATION, 1995, 94 (07) : 423 - 427
  • [46] Determination of the optimal minimum radioiodine dose in patients with Graves' disease: a clinical outcome study
    Howarth, D
    Epstein, M
    Lan, L
    Tan, P
    Booker, J
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE, 2001, 28 (10) : 1489 - 1495
  • [47] A retrospective study of clinical features and prognosis of patients with Graves' disease and ophthalmopathy
    Rui, Zhong Ying
    Yin, Xue
    Wang, Xuan
    Shen, Jie
    Zheng, Wei
    NUCLEAR MEDICINE COMMUNICATIONS, 2023, 44 (02) : 137 - 141
  • [48] Evaluation of radioiodine therapy with fixed doses of 10 and 15 mCi in patients with Graves' disease
    Canadas, Viviane
    Vilar, Lucio
    Moura, Euane
    Brito, Ana
    Castellar, Enio
    ARQUIVOS BRASILEIROS DE ENDOCRINOLOGIA E METABOLOGIA, 2007, 51 (07) : 1069 - 1076
  • [49] Elephantiasic Pretibial Myxedema with Graves' Disease: Spontaneously Induced and Dramatically Resolved after Radioiodine Treatment
    Yang, Jun
    Dong, Meng-Jie
    Xu, Qin
    EUROPEAN THYROID JOURNAL, 2020, 9 (01) : 55 - 56
  • [50] Late and transient increases in free T4 after radioiodine treatment for Graves' disease
    Stensvold, AD
    Jorde, R
    Sundsfjord, J
    JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION, 1997, 20 (10) : 580 - 584